I 
119TH CONGRESS 
1ST SESSION H. R. 5919 
To direct the Secretary of Veterans Affairs to conduct a review of opioid 
overdose deaths among veterans, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
NOVEMBER 4, 2025 
Mr. MURPHY (for himself and Mr. COURTNEY) introduced the following bill; 
which was referred to the Committee on Veterans’ Affairs 
A BILL 
To direct the Secretary of Veterans Affairs to conduct a 
review of opioid overdose deaths among veterans, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Veterans Heroin Over-
dose Prevention Examination Act’’ or the ‘‘Veterans 
HOPE Act’’. 
SEC. 2. FINDINGS; SENSE OF CONGRESS. 
(a) FINDINGS.—Congress finds the following: 
(1) New research shows that a dramatic rise in 
opioid overdose deaths among veterans in recent 
VerDate Sep 11 2014 
23:17 Nov 06, 2025
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5919.IH
H5919
ssavage on LAPJG3WLY3PROD with BILLS
years has happened increasingly among veterans 
dying from heroin and synthetic opioids. 
(2) Furthermore, patients of the Veterans 
Health Administration of the Department of Vet-
erans Affairs are seven times more likely to suffer 
from an opioid use disorder than commercially in-
sured patients. 
(3) Using records of the Veterans Health Ad-
ministration linked to National Death Index data, 
the veterans’ rate of overdose deaths from all opioids 
increased by 65 percent from 2010 to 2016, a rate 
change that includes adjustments for demographic 
changes in the veteran population over time. 
(4) Furthermore, among all opioid overdose de-
cedents, prescription opioid receipt within three 
months before death declined from 54 percent in 
2010 to 26 percent in 2016, yet veteran overdoses 
resulting in death from heroin, synthetic opioids 
such as fentanyl, and nonprescription opioids still 
occurred. 
(5) In fact, between 2010 and 2016, the vet-
eran death rate from heroin or from taking multiple 
opioids almost quintupled and the death rate from 
synthetic opioids such as fentanyl increased by more 
than five-fold. 
VerDate Sep 11 2014 
23:17 Nov 06, 2025
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5919.IH
H5919
ssavage on LAPJG3WLY3PROD with BILLS
(6) Trends would suggest that, while the aggre-
gate rise in opioid overdose deaths among veterans 
parallel those seen in the general population, the in-
crease occurred mainly because of a rise in deaths 
from nonprescribed sources such as heroin, fentanyl, 
other powerful synthetic opioids, or multiple opioids 
in concurrent use. 
(b) SENSE OF CONGRESS.—It is the sense of Con-
gress that further veterans overdose prevention efforts and 
research should extend beyond patients actively receiving 
opioid prescriptions. 
SEC. 3. REVIEW OF DEATHS OF VETERANS RELATING TO 
OPIOID USE. 
(a) REVIEW.—Not later than 18 months after the 
date of the enactment of this Act, the Secretary of Vet-
erans Affairs shall complete a review of the deaths of all 
covered veterans who died from opioid overdoses during 
the five-year period preceding the date of the enactment 
for this Act. 
(b) MATTERS INCLUDED.—The review under sub-
section (a) shall include the following: 
(1) The total number of covered veterans who 
died from opioid overdoses during the five-year pe-
riod preceding the date of the enactment of this Act. 
VerDate Sep 11 2014 
23:17 Nov 06, 2025
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5919.IH
H5919
ssavage on LAPJG3WLY3PROD with BILLS
(2) A summary of such veterans that includes 
the age, sex, race, and ethnicity of each such vet-
eran. 
(3) A comprehensive list of the medications pre-
scribed to, and found in the bodies of, such veterans 
at the time of death, specifically listing any medica-
tions that carry a black box warning, are off-label, 
or are psychotropic. 
(4) A summary of medical diagnoses by physi-
cians of the Department of Veterans Affairs that led 
to any prescribing of the medications referred to in 
paragraph (3). 
(5) The number of instances in which such a 
veteran was concurrently on multiple medications 
prescribed by physicians of the Department. 
(6) A summary of— 
(A) the average period that elapsed be-
tween the last prescription opioid receipt and 
the date of the death of such a veteran; and 
(B) the cause of death for each such vet-
eran. 
(7) The percentage of such veterans with com-
bat experience or trauma (including military sexual 
trauma, traumatic brain injury, and post-traumatic 
stress). 
VerDate Sep 11 2014 
23:17 Nov 06, 2025
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5919.IH
H5919
ssavage on LAPJG3WLY3PROD with BILLS
(8) Identification of medical facilities of the De-
partment with high prescription and drug abuse 
treatment rates for patients being treated at those 
facilities. 
(9) A description of policies of the Department 
governing the prescribing of medications referred to 
in paragraph (3). 
(10) A description of efforts by the Secretary to 
electronically track, collect, and properly dispose of 
prescription opioids that are either unused, past the 
prescription date, or not in the possession of the 
properly prescribed patient. 
(11) A description of any patterns apparent to 
the Secretary based on the review. 
(12) Recommendations for further action that 
would improve the safety and well-being of veterans 
and reduce opioid overdose rates for veterans, espe-
cially concerning research regarding such veterans 
who had not filed for a opioid prescription in the 
three months before death by overdose. 
(c) PUBLIC AVAILABILITY.—Not later than 45 days 
after the completion of the review under subsection (a), 
the Secretary shall— 
(1) submit to Congress a report on the results 
of the review; 
VerDate Sep 11 2014 
23:17 Nov 06, 2025
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H5919.IH
H5919
ssavage on LAPJG3WLY3PROD with BILLS
(2) make such report publicly available; and 
(3) provide to the Committees on Veterans’ Af-
fairs of the House of Representatives and the Senate 
a briefing on such review. 
(d) DEFINITIONS.—In this section: 
(1) The term ‘‘black box warning’’ means a 
warning displayed within a box in the prescribing in-
formation for drugs that have special problems, par-
ticularly ones that may lead to death or serious in-
jury. 
(2) The term ‘‘covered veteran’’ means any vet-
eran who received hospital care or medical services 
furnished by the Department of Veterans Affairs 
during the five-year period preceding the death of 
the veteran. 
Æ 
VerDate Sep 11 2014 
23:17 Nov 06, 2025
Jkt 069200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6301
E:\BILLS\H5919.IH
H5919
ssavage on LAPJG3WLY3PROD with BILLS